<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5502">
  <stage>Registered</stage>
  <submitdate>3/04/2008</submitdate>
  <approvaldate>3/04/2008</approvaldate>
  <nctid>NCT00654550</nctid>
  <trial_identification>
    <studytitle>A Study to Assess the Safety, Tolerability and Effect of Nexagon Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness</studytitle>
    <scientifictitle>A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NEX-OCU-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Corneal re-Epithelialization</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nexagon or Nexagon vehicle

Experimental: 1 - 


Treatment: drugs: Nexagon or Nexagon vehicle
Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events</outcome>
      <timepoint>30 days post-application</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the clinical effect of Nexagon</outcome>
      <timepoint>30 days post-application</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female pre-presbyopic myopes.

          -  Aged between 20 and 50 years inclusive.

          -  Females are eligible to participate only if they are currently non-pregnant and
             non-lactating. Females of child-bearing potential must commit to consistent and
             correct use of an acceptable method of birth control.

          -  Subjects willing and able to undergo bilateral PRK for the correction of their myopia.

          -  Subjects with MRSE &lt;6.0 D, with less than 2.0 D of astigmatism.

          -  No more than 1.0 D of refractive difference between eyes.

          -  Stable prescription in both eyes as defined by &lt;0.25 D change over the preceding 2
             years.

          -  Subjects who are able to comply with all study procedures, including wearing a soft
             bandage contact lens in the immediate postoperative period.

          -  Subjects who are willing and able to give written informed consent to take part in the
             study.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects who have a past or present disease, which as judged by the investigator may
             affect the safety of the subject or the outcome of the study.

          -  Subjects who have previously had corneal surgery.

          -  Subjects who require Mitomycin C following their PRK.

          -  Subjects with any ocular disease or corneal abnormality, including but not limited to:

               -  Decreased corneal sensation / neurotrophic cornea;

               -  Corneal vascularization;

               -  Keratoconus;

               -  Keratoconjunctivitis sicca requiring chronic treatment;

               -  Lagophthalmos;

               -  Blepharitis;

               -  History of infectious keratitis;

               -  History of glaucoma or intraocular pressure of &gt;21 mmHg or use of glaucoma
                  medications;

               -  Significant dry eye disease that requires regular topical treatment;

               -  Corneal thickness &lt;480 Âµm at the thinnest point, and

               -  Posterior elevation &gt;40 mmHg.

          -  Subjects with corneal haze &gt;+1 as assessed using the grading scale in the protocol.

          -  Subjects who require any topical ophthalmic medication other than the pre- and
             postoperative regimen defined in the study protocol.

          -  Subjects with:

               -  Diabetes;

               -  Collagen disorders associated with autoimmune diseases, e.g., lupus, rheumatoid
                  arthritis;

               -  Severe atopic disease;

               -  Any systemic disease or condition where the subject is immunocompromized.

          -  Subjects who require any systemic medication that affects healing, e.g., steroids,
             hormone replacement therapy.

          -  Subjects who are taking amiodarone, long acting anticholinergics, e.g., atropine,
             scopolamine, or medications or agents that can cause dry eye.

          -  Subjects who have participated in a clinical trial within the 30 days prior to the
             date on which PRK is scheduled.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CoDa Therapeutics Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 1 randomized, prospective, double-masked, vehicle-controlled, dose-escalation study to
      evaluate the safety, tolerability and clinical effect of Nexagon in subjects following
      bilateral PRK for the correction of mild to moderate myopia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00654550</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sue Ormonde, MD, FRC Ophth, FRANZCO</name>
      <address>Auckland Eye</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>